SAGE Therapeutics公司2024年第三季度财报公布后股价盘后大跌15.09%,引发市场广泛关注。财报数据显示,SAGE Therapeutics在2024年第三季度继续亏损,亏损金额较去年同期大幅扩大。
具体来看,SAGE Therapeutics报告2024年第三季度调整后每股亏损1.53美元,而去年同期则为每股收益3.37美元。公司当季度亏损高达9355万美元,亏损幅度大大超出市场预期。
尽管SAGE Therapeutics第三季度营收同比大增337.1%至1187万美元,但显然营收增长未能抵消成本费用的大幅上升,导致公司季度亏损明显扩大。市场对公司业绩表现出乎意料的亏损预期,在财报公布后迅速做出了股价大跌的反应。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.